Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma.

Slides:

Advertisements

Similar presentations

Blood lactate level during extracorporeal life support as a surrogate marker for survival Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,

Advertisements

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.

Society of Thoracic Surgeons 2008 cardiac risk models predict in-hospital mortality of heart valve surgery in a Chinese population: A multicenter study

Manuel J. Antunes, MD, PhD, DSc

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Stephen R. Broderick, MD, MPHS

Two decades of pediatric lung transplant in the United States: Have we improved? Farhan Zafar, MD, Jeffrey S. Heinle, MD, Marc G. Schecter, MD, Joseph.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: A multicenter comparative trial

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, MD, MSc, Ronald Feld, MD,

Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial Niv Ad, MD, Sari D. Holmes,

Outcome of 200 patients after an extracardiac Fontan procedure

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

The impact on survival of positive intraoperative pleural lavage cytology in patients with non–small-cell lung cancer Keiju Aokage, MD, Junji Yoshida,

Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival Zarah Glad.

Ultrasound, endoscopy, and the recurrent nerve

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

Blood lactate level during extracorporeal life support as a surrogate marker for survival Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,

Intrinsic cardiac stem cells are essential for regeneration

Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy Hasan Fevzi Batirel, MD,

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer Walter Weder, MD, Stéphane Collaud, MD,

Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database

How should we treat air leaks?

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice Tom.

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma Yasuhiro Tsutani, MD, PhD, Yoshihiro.

The lord of the rings Antonio Miceli, MD, PhD

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Outcome after surgery for prosthetic valve endocarditis and the impact of preoperative treatment Herko Grubitzsch, MD, PhD, Andreas Schaefer, Christoph.

Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma Po-Kuei Hsu, MD,

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Nationwide cohort study of mitral valve repair versus replacement for infective endocarditis Hsiu-An Lee, MD, Yu-Ting Cheng, MD, Victor Chien-Chia Wu,

Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model.

It's not “just a shunt” but sometimes it should be…

Bartley P. Griffith, MD, FACS, FRCS

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients Raja.

The influence of retransplantation on survival for pediatric lung transplant recipients Ryuichi Waseda, MD, PhD, Alberto Benazzo, MD, Konrad Hoetzenecker,

Stephen R. Broderick, MD, MPHS

Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma.

Shawn S. Groth, MD, MS, R. Taylor Ripley, MD, Bryan M. Burt, MD

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Niv Ad, MD, Lawrence M. Wei, MD

Clinical Relevance of Our Multimodality Prognostic Score

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, Timothy Akhurst, MD, Mithat Gonen, PhD, Maureen Zakowski,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Do statins delay the progression of aortic stenosis?

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

Raja M. Flores, MD The Journal of Thoracic and Cardiovascular Surgery

Therapeutic R2 resection for pleural mesothelioma

The Journal of Thoracic and Cardiovascular Surgery

“The more things change…”: The challenges ahead

Apples remain apples NO matter what

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Zone zero thoracic endovascular aortic repair is all about “location, location, location” Kevin L. Greason, MD The Journal of Thoracic and Cardiovascular.

Presentation transcript:

Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery Lukas Frischknecht, MD, Mayura Meerang, PhD, Alex Soltermann, MD, Rolf Stahel, MD, Holger Moch, MD, Burkhardt Seifert, PhD, Walter Weder, MD, Isabelle Opitz, MD The Journal of Thoracic and Cardiovascular Surgery Volume 149, Issue 6, Pages 1539-1547.e1 (June 2015) DOI: 10.1016/j.jtcvs.2015.01.065 Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Immunohistochemical staining of ERCC1 and RRM1: examples of low (A) and high (B) ERCC1 staining, and low (C) and high (D) cytoplasmic RRM1. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 1539-1547.e1DOI: (10.1016/j.jtcvs.2015.01.065) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Box plots of marker expression during induction chemotherapy in paired pre- and postchemotherapy samples (Wilcoxon signed-rank test). A, Increase in cytoplasmic RRM1 expression after chemotherapy (n = 64): median expression prechemotherapy: 1.00 (interquartile range [IQR], 0.75-1.00), median expression postchemotherapy: 1.25 (IQR, 1.00-2.00) (P < .0005). B, Decrease in nuclear RRM1 after chemotherapy (n = 64): median expression prechemotherapy: 0.10 (IQR, 0.00-1.50), median expression postchemotherapy: 0.00 (IQR, 0.00-0.00) (P < .0005). C, No significant decrease in nuclear ERCC1 expression after chemotherapy (n = 84): median expression prechemotherapy: 2.00 (IQR, 2.00-3.00), median expression postchemotherapy: 2.00 (IQR, 1.50-2.25) (P = .07). RRM1, Ribonucleotide reductase M1; ERCC1, Excision repair cross-complementation group 1. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 1539-1547.e1DOI: (10.1016/j.jtcvs.2015.01.065) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Kaplan–Meier survival curves according to dichotomized marker expression. The tables show the FFR/OS with 95% confidence interval at 1, 2, and 3 years. A, Expression of nuclear RRM1 in prechemotherapy biopsies is associated with a prolonged FFR (no RRM1 expression [n = 36]: median FFR 13 months [95% CI, 10-16], RRM1 expression [n = 35]: median FFR 19 months [95% CI, 15-22], log-rank test P = .03 [n = 71]). In the subgroup receiving platinum/gemcitabine treatment, both the FFR (B) and OS (C) were significantly longer in the patients expressing nuclear RRM1 in their pretreatment biopsies: no RRM1 expression (n = 21): median FFR 14 months (95% CI, 8-19), RRM1 expression (n = 11): median FFR 24 months (95% CI, 6-41), P = .02; no RRM1 expression (n = 21): median OS 20 months (95% CI, 16-25), RRM1 expression (n = 11): median OS: 32 months (95% CI, 13-51), P = .03. D, Low expression of nuclear ERCC1 in prechemotherapy biopsies is associated with longer FFR (low ERCC1 [≤2.00]: median FFR 16 months [95% CI, 12-20], high ERCC1 expression [>2.00]: median FFR 15 months [95% CI, 11-19], P = .04). RRM1, Ribonucleotide reductase M1; CTX, chemotherapy; FFR, freedom from recurrence; OS, overall survival; ERCC1, excision repair cross-complementation group 1. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 1539-1547.e1DOI: (10.1016/j.jtcvs.2015.01.065) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Consort graph of the patient cohort. EPP, Extrapleural pneumonectomy; MPM, malignant pleural mesothelioma; TMA, tissue microarray. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 1539-1547.e1DOI: (10.1016/j.jtcvs.2015.01.065) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions